The Drug That Ate Your
Business Model
GLP-1 receptor agonists are no longer just a clinical breakthrough — they are a macro-economic force. About one in eight US adults is currently taking one, and nearly one in five has taken one at some point. Industries built on habitual craving are watching their unit economics shift underneath them.
GLP-1 receptor agonists are emerging as a significant disruption to consumer behavior, challenging long-standing assumptions that have shaped food and consumer strategies for decades. The question is no longer if your category is exposed, but whether you are attempting to defend a status quo that has already been reshaped by changes in appetite, food preferences, and reward-related behaviors.
This decision brief examines this transition through the lenses of neurobiological disruption, emerging clinical liabilities, and the unclaimed platform opportunity to show exactly when leaders should defend, pivot, or build new models entirely.
Key Findings
1.
Disruption goes beyond the gut. GLP-1 drugs act on both appetite and reward-related brain pathways. This is not only about hunger. It is also about reduced cravings for food, with emerging evidence suggesting effects on alcohol and, more tentatively, nicotine. Any business model built on habitual repurchase is now vulnerable.
2.
Satiety is solved. Micronutrient density is not. The drug already suppresses appetite. Products offering more fullness are redundant. The real opportunity lies in micronutrient integrity, calcium, vitamin D, and magnesium, to bridge the potential intake gaps.
3.
The bone loss risk is documented. The product response is not. Significant bone mineral density loss has been observed in users without exercise protocols. These clinical risks are silent, can develop without symptoms, and represent a future liability for any company failing to provide whole-person care.
4.
The revenue headwind is neurochemical, not seasonal. This is not a temporary diet trend. The 41% reduction in heavy drinking days and emerging evidence of reduced nicotine craving point to neurochemical shifts that extend beyond appetite. The pressure on affected revenue models is structural.
5.
A 57-point support gap remains unclaimed. 74% of users want mental health support. Only 17% receive it. This misalignment between demand and provision is the primary entry point for a new category of integrated care platforms.
6.
The playbook has been contradicted. Assumptions that muscle loss is minor or that protein shakes alone solve the depletion problem are being contradicted by clinical evidence. Strategic resilience now requires a fundamental update to consumer health models.
$64.4B
global GLP-1 market size (2025)
1 in 8
U.S. adults have used GLP-1 agonists (2024)
-5.3%
average grocery spend drop within 6 months of starting therapy
$114B
projected global market opportunity for obesity drugs by 2030
The death of the default craving
The entire food industry is preparing for a consumer who eats less. That is the wrong consumer to prepare for.
GLP-1 receptor agonists do not simply tell the stomach to feel full. The drug acts at receptors in the hindbrain and circumventricular organs, which influence mesolimbic circuits governing reward, motivation, and craving. These effects extend beyond food, with emerging evidence suggesting reduced cravings for alcohol and nicotine. Weight loss is driven largely by reduced energy intake, through both appetite and reward-related mechanisms. Companies building strategy around the appetite alone may be missing a broader shift in consumer behavior.
The scale of what is already in market makes this a present-tense problem, not a future-state one. One in eight U.S. adults has already used a GLP-1 agonist. The number of U.S. patients without diabetes starting GLP-1 treatment grew 700% between 2019 and 2023. Grocery spending among GLP-1 users dropped more than 5% within six months of starting treatment. Fast food and limited-service restaurant spending fell 8%. The largest declines were concentrated in calorie-dense processed categories, including a 10.1% drop in savory snacks. Every industry built on habitual consumption is already operating inside this disruption. Most are still treating it as a dietary trend.
Gareth Armanious, PhD
Technical Director | PreScouter
The instinct is to look at GLP-1 through a food and beverage lens because that is where the volume signal is clearest. But the dopamine pathway does not distinguish between a bag of chips and a cigarette. The industries that understand they are looking at a reward disruption event, not a satiety trend, are the ones that will position early enough to matter.
The data confirms this is not a dietary shift. In controlled trials for alcohol use disorder, semaglutide drove a 41% reduction in heavy drinking days. The drug is not helping consumers make better choices. It is changing what they want.
General grocery
−5.5%spending
Within 6 months of GLP-1 adoption
Savory snacks
−10.1%spending
Within 6 months of GLP-1 adoption
Fast food / dining
−8.0%spending
Within 6 months of GLP-1 adoption
The household amplifier
Exposure within the home spreads more rapidly than individual patient counts. Circana estimates that households using GLP-1 medications already represent about 23% of U.S. households and are projected to account for 35% of all U.S. food and beverage units sold by 2030.
35%
U.S. F&B unit sales by 2030 (Numerator)
Carrie Gabriel, MS, RDN
Registered Dietitian | CulinArt Group
There is more of a tolerance vs. appetite decision when it comes to eating. People will pull back on heavier, greasier, spicier foods if it induces nausea, acid reflux, or general GI discomfort. Impulse snacking subsides, food noise is lowered, and people become more selective, leaning toward protein-forward, simple meals that make them feel their best physically.
Solving a problem the drug already solved
The food and supplement industry’s response to GLP-1 has been fast, visible, and largely misdirected. Nestlé launched Vital Pursuit, a high-protein, portion-controlled meal line positioned for GLP-1 users. Herbalife introduced a GLP-1 Nutrition Companion built around protein shakes and fiber. The Vitamin Shoppe followed with a dietitian-formulated nutrient powder. The category is moving. The underlying logic is not holding up.
These products are built around a similar premise: that GLP-1 users need additional support around satiety and nutrition. Appetite suppression is the one thing the drug handles without assistance. A study drawing on a sample of 22,691 U.S. households found that households with at least one GLP-1 user reduced grocery spending by 5.3% within six months of starting treatment. These are not consumers struggling to eat less. They are already eating significantly less, and the question that matters is whether what they do eat contains enough nutritional density to prevent physiological decline. Formulating for satiety in this population is solving a problem the prescription already solved.
Expert Commentary
Victoria Yeung, MBS
Senior Project Architect | PreScouter
The products that will matter in three years are being built on the biology of this specific population, not on what worked for diet culture in 2015. In CPG product development, the instinct is always to lead with the benefit the consumer can feel immediately. Satiety is tangible. Bone density is not. The problem is that GLP-1 users are not a standard calorie-restriction cohort. Their nutritional exposure window is compressed in ways that legacy formulation playbooks were never designed to address.
The real problem is the risk of inadequate nutrient intake. When caloric intake drops sharply and stays low, the body’s access to micronutrients drops with it. Calcium, vitamin D, and magnesium are among the nutrients that may be inadequately consumed. Protein alone does not adequately address the broader nutritional needs of GLP-1 users. Tirzepatide trials show that roughly 25% of weight lost with tirzepatide is lean mass, not fat, and the consequences compound with age. For older adults, that lean-mass loss occurs against a baseline of age-related declines in muscle and bone. The brands leading the current product wave are fortifying against the wrong deficit.
- Research Publication
Get the complete GLP-1 strategic disruption analysis
A deep-dive into how GLP-1 drugs are changing consumer cravings, category demand, and long-term market strategy. The brief examines exposed industries, nutrient gaps, and the platform opportunities emerging around integrated care.
The invisible skeletal deficit
Muscle loss from GLP-1 therapy has entered the mainstream conversation. Fitness brands are responding. Protein is being repositioned. Noom built a Muscle Defense protocol. Equinox launched a GLP-1-specific strength program. The industry has identified lean mass preservation as the primary physiological challenge and organized around it. That response is correct and insufficient, because it is addressing the visible risk while another clinically relevant risk may develop undetected.
Bone loss does not show up in the mirror. It does not produce fatigue or weakness that a user can attribute to their medication. It does not appear in any consumer-facing metric. It shows up years later as a fracture, a density scan, a diagnosis. A 2024 randomized study tracked bone mineral density at the hip, spine, and forearm across four intervention groups over 52 weeks. The group receiving liraglutide without exercise showed significant BMD reductions at both the hip and lumbar spine by the end of the study. The exercise-plus-liraglutide group showed substantially less loss, pointing directly at the intervention.
Expert Commentary
Thuy Ngo, PhD
Project Architect | PreScouter
The bone density data is not ambiguous. What is ambiguous is whether the industry will move on it. The clinical signal is already there. The product response is not. That is a window, and windows in consumer health tend to close fast once the first brand names the category correctly. Only 17% of current GLP-1 users are in behavioral therapy, and 39% are not enrolled in any whole-person health program at all. The population most at risk is the one least likely to be receiving the protocol that mitigates it.
The nutritional gap that drives bone loss is also more complex than the muscle conversation acknowledges. Protein matters for lean mass, while bone health also depends on adequate calcium, vitamin D, and other nutrients involved in bone metabolism. A GLP-1 user relying on a high-protein shake may still have broader nutritional needs that are relevant to bone health. Existing GLP-1 products already combine protein with broad vitamin and mineral support, but there remains an opportunity to address muscle preservation and bone health together with greater specificity for this population. That gap is the opportunity, and it is sitting open right now.
Download the GLP-1 Strategic Report
Get the complete analysis, including detailed category risk profiles, potential nutrient gaps data, and the full expert panel commentary.
Rituals without rewards: alcohol & tobacco
The category-level reading of GLP-1 inside most beverage alcohol strategy decks is that the impact is real but manageable, a modest volume headwind concentrated among health-conscious consumers who were probably drinking less anyway. That conclusion misses what the mechanism is actually doing.
The reduction in alcohol consumption among GLP-1 users may extend beyond the downstream effect of eating less, feeling healthier, or making better lifestyle choices. GLP-1 receptors are expressed in brain reward circuitry, and preclinical evidence shows that GLP-1 receptor activation can dampen dopamine signaling associated with reward. Emerging clinical evidence also suggests effects beyond food, including reduced alcohol and nicotine craving.
The tobacco picture is structurally identical and strategically worse. A 2021 randomized pilot trial found that exenatide raised smoking abstinence rates from 26.8% to 46.3% when combined with standard nicotine patch therapy. The mechanism here is the same: preclinical data indicate that GLP-1 receptor activation can modulate mesolimbic reward circuitry and reduce nicotine reinforcement.
Expert Commentary
Jorge Hurtado, PhD
Senior Analyst | PreScouter
GLP-1 is a faster and more persistent version of that shift, because the mechanism is not cultural. It is chemical. The historical precedent that matters here is not in pharma. It is in how the alcohol industry responded to the drunk driving campaigns of the 1980s, which created an entirely new non-alcoholic occasion. The brands that moved early built category leadership that held for decades. The ones that waited defended volume until they couldn’t.
The alcohol industry at least retains the social occasion, the glass, the ritual, the moment, and can credibly pivot toward functional non-alcoholic beverages that capture it. Tobacco has no equivalent. The hand-to-mouth ritual can be addressed with nicotine-free inhalers, but the craving mechanism that makes tobacco sticky overlaps with the reward pathways GLP-1 therapies appear to modulate. No validated GLP-1-compatible tobacco product exists today. There is only earlier or later portfolio diversification.
Signal attenuation
Alcohol reward erasure
Neural response reduction across heavy use populations.
64%
Reduction in heavy drinking days within 8 weeks
Reinforcement decoupling
Tobacco & nicotine erasure
Systemic failure of the nicotine–dopamine reinforcement loop.
Nearly 2x increase vs standard therapy alone
The Dopamine Loop Disruption
Preclinical evidence indicates that GLP-1 receptor activation in reward-related circuits can reduce the reinforcing value of nicotine and alcohol. This is not a choice-based lifestyle shift; it is a fundamental neurochemical decoupling of reward and stimulus.
The unclaimed strategic platform
The conversation about GLP-1 opportunities has been organized almost entirely around products. Which supplement wins the micronutrient gap. Which beverage brand captures the alcohol occasion. Which fitness platform builds the muscle preservation protocol. Those are real opportunities and they are being pursued. What remains underdeveloped at a meaningful scale is the position that sits above all of them: the integrated support relationship with the GLP-1 user across the full arc of their treatment journey.
- Integrated Platform Single user relationship 01
- Behavioral Health Mood & cravings management 02
- Nutrition Counseling Micronutrient optimization 03
- Pharmacological Monitoring Protocol & adherence 04
Market imbalance
The behavioral support gap
The platform opportunity
57 percentage point strategic void
The behavioral health data makes the gap visible. A 2024 survey of 300 GLP-1 users conducted by MARC Research in partnership with Evernorth found that 74% were interested in mental health support, while only 17% used behavioral health or talk therapy. Sixty-three percent believed they would achieve better health with mental health support while taking GLP-1s.
The transition crisis
Among former users who had stopped treatment, 48% reported worsened mental health in the prior year, compared to 29% of current users.
48%
Worsened mental health post-drug
These numbers do not describe a population with a side effect problem. They describe a population undergoing a significant behavioral change, with a clear demand for support that the current care infrastructure is not meeting. The drug is doing something real to how these people experience reward, motivation, and craving. The care model has not caught up.
The Wisp-Nourish partnership is the clearest early signal of what the integrated model looks like in practice. Wisp, a women’s health telehealth provider, partnered with Nourish to offer nutrition counseling to GLP-1 patients as part of their weight management program, accessible through insurance or discounted self-pay. It addresses nutrient intake, supports behavioral change through personalized guidance, and extends the care relationship beyond the prescription.
It is not comprehensive, but it is the right shape. The brands that build this model at scale, combining telehealth, nutrition counseling, fitness programming, behavioral health support, and pharmacological monitoring into a single user relationship, will own something no supplement SKU or protein shake can compete with. That is not a product. That is a platform. And no single platform has yet fully integrated all of these elements at scale.
Expert Commentary
Victoria Yeung, MBS
Senior Project Architect | PreScouter
The brands that see it as a product adjacency will build supplements. The brands that see it as a platform opportunity will build something that compounds. What the data tells you is that GLP-1 users are not passive. They are actively seeking support that the current market is not providing. Seventy-four percent raising their hand for behavioral help is not a niche signal. That is a category waiting to be built.
Five questions that apply here, and to every large disruption
01
Are you solving for the mechanism or the symptom?
In GLP-1, companies building only for appetite suppression are solving for part of the mechanism. The broader disruption also involves reward pathways, with effects extending beyond food into alcohol and, more tentatively, nicotine. Every large disruption has an equivalent distinction between what is visibly happening and what is actually driving it. The strategy built on the visible thing will be outpaced by the one built on the mechanism.
02
What does your portfolio look like if the craving disappears?
GLP-1 does not reduce consumption by making people more disciplined. It can also reduce reward and craving signals that help reinforce repeated behavior. Any business that depends on habitual repurchase should stress-test its model against a consumer who no longer experiences the craving that drove the habit. If the value proposition only works when the want is intact, the brand is more exposed than the revenue line currently suggests.
03
Are you moving on the invisible risk or waiting for the visible one?
Bone loss is not readily visible in consumer complaints or product returns. It is showing up in clinical data that most product teams have not read. The visible risk in GLP-1 is lean mass loss, and the market is already responding. The invisible risk is bone density decline, and the market is not. In every disruption, the invisible risk is where the first-mover advantage is largest and the window is longest, because most competitors are still watching the visible one.
04
Is the gap between what your customer needs and what you offer a problem or a position?
Seventy-four percent of GLP-1 users want behavioral support. Seventeen percent are receiving it. That 57-point gap is not a failure of awareness. It is a market that has not yet been built. In any disruption, the largest unmet need is not always obvious to the incumbents closest to it. The question is whether you see the gap as someone else’s problem to solve or as the highest-value position available to you.
05
Does your response timeline survive the actual pace of adoption?
The number of U.S. patients without diabetes starting GLP-1 treatment grew 700% in four years. Oral formulations are positioned to lower a key adoption barrier by eliminating the need for injections. The planning horizon most companies are using for their GLP-1 response is not calibrated to that adoption curve. Test every strategic response against a scenario where penetration doubles in the next 24 months. If the response only works given more time, it is already late.
Contributing Experts
Gareth Armanious, PhD
Technical Director | PreScouter
Gareth is the Technical Director of Food & Beverage at PreScouter, where he’s driven strategy and scientific research for Fortune 500s since 2015. He built and leads the F&B team, architecting systems and services that shaped company-wide execution. His expertise spans food, beverage, and life sciences, rooted in a research background in membrane protein biochemistry and prior coordination roles in oncology research.
Victoria Yeung, MBS
Senior Project Architect | PreScouter
Victoria is one of PreScouter’s Project Architects specializing in the Food & Beverage industry. She holds a BS and MBS in Food Science from Rutgers University, where her research focused on identification of photosensitizers for the inactivation of foodborne pathogens. Prior to joining PreScouter, Victoria worked as a scientist at a Fortune 500 consumer packaged goods company, specializing in flavor technology and driving innovations across R&D.
Thuy Ngo, PhD
Project Architect | PreScouter
Thuy earned her PhD degree in Advanced Fusion Technology from Konkuk University, and her Advanced Master in Intellectual Property Law and Knowledge Management from Maastricht University. Before joining PreScouter, she worked as a Research Professor in the field of Structural Biology at Konkuk University where she researched antibacterial drugs and industrial enzymes by leveraging protein tertiary structure. At PreScouter, she specializes in and manages service delivery for clients in the Food&Bev and Life Sciences sectors. She is currently based in Ho Chi Minh City, Vietnam.
Jorge Hurtado, PhD
Senior Analyst | PreScouter
Jorge works as a Senior Analyst at PreScouter. His expertise spans a broad spectrum of technological fields. He holds a Master’s degree in Conservation and Development, a Ph.D. in Biology from the University of Florida and Syracuse University, respectively, and a diploma in Green Economy from Toronto Metropolitan University.
Carrie Gabriel, MS, RDN
Registered Dietitian | CulinArt Group
Carrie is a registered dietitian with over 13 years of experience, known for blending evidence-based nutrition with practical, culinary-focused guidance. Her work spans recipe development and brand collaborations, as well as nutrition counseling, particularly with women navigating perimenopause, menopause, and GLP-1–related weight management. Carrie specializes in helping people build confidence in home cooking and using whole foods in realistic ways that account for time, budget, and convenience constraints.